ARE YOU A LIFE SCIENCE COMPANY WITH GROWTH AMBITIONS?

We empower Life Science companies to grow to their full potential so that more people can benefit from great innovations and solutions

REPORT IS READY

GROWTH IN "THE NEW NORMAL"

One in 200 has interviewed 25 leaders within the Swedish Life Science industry on how the Corona pandemic has affected their businesses and ability to grow.

On February 2nd, One in 200 will discuss the report in a webinar with Stockholm Science City, Vinnova, HealthCap and Biostock.

Welcome, we hope you can attend!

GET REPORT

WEBINAR REGISTRATION

GROWING IS A BALANCING ACT

- ONLY ONE IN 200 SUCCEED

We support SMEs to prepare and develop the mindset, structures and skills, needed to master the balancing act of growing - becoming One in 200.

Together with you, we identify the core challenges you need to focus on. Then our team will suggest a plan to support your specific situation - based on our experience from leading roles in growing organisations, management consulting and life science expertise.

WHY WORK WITH US?

We have done it before

We are great facilitators and we deliver result fast

We know Life Science

HOW WE HAVE SUPPORTED COMPANIES TO GROW

WE ARE HAPPY TO TELL YOU MORE!

PROFITABILITY PROGRAM

Including activities to increase revenues by identifying qualitative customer leads, and cost savings through process enhancements and digitalisation.

GROWTH IS A MULTI-FACETED TASK WITH DIFFERENT CHALLENGES OVER TIME

To penetrate the market you need to have an excellent offering that meet a clear customer demand, the right pricing and efficient sales channels. You also need a scalable business model, the right team and timing, an efficient delivery capability, the right core competences and resources, an agile organisation, customer driven development processes, and data driven decisions. Just to name a few.

As a Life Science company, you also need to juggle complicated technical challenges, high cost development cycles, complex business models, clinical trials, regulatory affairs, and questions around reimbursement and market access.